Orthofix Medical (NASDAQ:OFIX) Issues FY 2019 Earnings Guidance

Orthofix Medical (NASDAQ:OFIX) issued an update on its FY 2019 earnings guidance on Monday morning. The company provided EPS guidance of $1.75-1.82 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.78. The company issued revenue guidance of $472-477 million, compared to the consensus revenue estimate of $473.76 million.Orthofix Medical also updated its FY19 guidance to $1.75-1.82 EPS.

Shares of NASDAQ OFIX traded up $0.85 during trading on Tuesday, reaching $51.72. The company had a trading volume of 3,203 shares, compared to its average volume of 158,127. Orthofix Medical has a 12-month low of $47.79 and a 12-month high of $74.44. The stock has a market cap of $1.01 billion, a PE ratio of 26.19, a PEG ratio of 2.98 and a beta of 0.42. The business’s 50-day moving average is $51.65. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.28 and a current ratio of 3.52.

Orthofix Medical (NASDAQ:OFIX) last released its earnings results on Monday, August 5th. The medical device company reported $0.28 EPS for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.12). Orthofix Medical had a return on equity of 10.45% and a net margin of 2.09%. The company had revenue of $115.85 million during the quarter, compared to analysts’ expectations of $115.17 million. During the same period in the prior year, the company posted $0.42 earnings per share. The company’s revenue was up 3.9% on a year-over-year basis. Research analysts forecast that Orthofix Medical will post 1.77 EPS for the current year.

A number of equities research analysts have recently commented on OFIX shares. Zacks Investment Research cut Orthofix Medical from a strong-buy rating to a hold rating in a research note on Wednesday, July 10th. ValuEngine cut Orthofix Medical from a buy rating to a hold rating in a research report on Saturday, May 18th. BidaskClub raised Orthofix Medical from a sell rating to a hold rating in a research report on Thursday, August 1st. Finally, TheStreet cut Orthofix Medical from a b+ rating to a c+ rating in a research report on Thursday, May 9th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The company presently has an average rating of Hold and an average price target of $60.00.

In related news, CEO Brad Mason sold 10,668 shares of the stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $53.71, for a total transaction of $572,978.28. Following the sale, the chief executive officer now directly owns 165,120 shares of the company’s stock, valued at $8,868,595.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 5.80% of the company’s stock.

About Orthofix Medical

Orthofix Medical Inc, a medical device company, provides musculoskeletal healing products and therapies worldwide. It operates through four segments: Bone Growth Therapies, Spinal Implants, Biologics, and Orthofix Extremities. The Bone Growth Therapies segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion and are indicated as treatment to enhance fusion success rates in cervical and lumbar spine, as well as a therapeutic treatment for non-spinal appendicular fractures.

Featured Story: The components of the Stochastic Momentum Index

Earnings History and Estimates for Orthofix Medical (NASDAQ:OFIX)

Receive News & Ratings for Orthofix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix Medical and related companies with MarketBeat.com's FREE daily email newsletter.